Published on
Apr 14, 2025
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat ...
– Recognizes potential of off-the-shelf CAR T-cell therapy to address significant unmet need and enables increased dialogue with FDA throughout the development process – RMAT review by FDA included initial clinical safety and activity data from ongoing …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
